SECURITIES AND EXCHANGE COMMISSION
FORM 8-K
CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (date of earliest event reported): July 29, 2004
Noven Pharmaceuticals, Inc.
11960 S.W. 144th Street, Miami, Florida 33186
305-253-5099
| Incorporated under the laws of the | Commission File Number | I.R.S. Employer Identification Number | ||
| State of Delaware | 0-17254 | 59-2767632 |
Item 7. Exhibits
(c) Exhibits.
99.1
|
Press release dated July 29, 2004 announcing the financial results of Noven Pharmaceuticals, Inc. for the quarter ended June 30, 2004. |
Item 12. Results of Operations and Financial Condition
On July 29, 2004, Noven issued a press release announcing its financial results for the quarter ended June 30, 2004. This press release, a copy of which is attached hereto as Exhibit 99.1, is “furnished” and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or incorporated by reference into a filing under the Securities Act of 1933 or the Exchange Act.
-2-
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
| NOVEN PHARMACEUTICALS, INC. |
||||
| /s/ Jeffrey F. Eisenberg | ||||
| Jeffrey F. Eisenberg | ||||
| Vice President, General Counsel and Corporate Secretary | ||||
Date: July 29, 2004
-3-